Liraglutide as additional treatment for type 1 diabetes.
about
Lost in translation: endoplasmic reticulum stress and the decline of β-cell health in diabetes mellitusEmerging gliptins for type 2 diabetes.GLP-1 Agonists in Type 1 Diabetes Mellitus.Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial.Longstanding insulin dependent diabetics may not require insulin after the introduction of GLP-1 analogues.Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.Nutrient induced type 2 and chemical induced type 1 experimental diabetes differently modulate gastric GLP-1 receptor expression.Exenatide exerts a potent antiinflammatory effect.Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.Evidence That in Uncontrolled Diabetes, Hyperglucagonemia Is Required for Ketosis but Not for Increased Hepatic Glucose Production or Hyperglycemia.Stabilization of postprandial blood glucose fluctuations by addition of glucagon like polypeptide-analog administration to intensive insulin therapy.Liraglutide for treating type 1 diabetes.A computational systems analysis of factors regulating α cell glucagon secretion.Synergy Between Gαz Deficiency and GLP-1 Analog Treatment in Preserving Functional β-Cell Mass in Experimental Diabetes.Glucagon-like peptide-1 analogues: An overview.Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial.Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus.Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges.A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes.Potential role of non-insulin adjunct therapy in Type 1 diabetes.Recent advances in incretin-based therapies.Individualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician.Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1.β-Cell differentiation and regeneration in type 1 diabetes.An update on the pharmacotherapy options for pediatric diabetes.Evidence-based practice use of incretin-based therapy in the natural history of diabetes.GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.Management of Severe Insulin Resistance in Patients with Type 1 Diabetes.The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus.Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes.Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs under Development.Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus.Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review.Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach.Weight Management in Patients with Type 1 Diabetes and Obesity.Moving beyond subcutaneous insulin: the application of adjunctive therapies to the treatment of type 1 diabetes.Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes.Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes.The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus.
P2860
Q26864403-92BCF678-7259-4D47-A5DA-6A436BAF1890Q34347884-4EC4EC61-E984-430D-A384-894083077812Q34677451-C0B4ACFE-2048-425F-9707-2793DB28C6D0Q34813843-02EBA2DD-B7C6-4C3A-A227-131453D79545Q35175857-86311606-693D-47A4-9D4B-FB05385CEFF3Q35331836-D186B061-E3E2-405D-A567-FB41F140C7F6Q35372850-2695AEDE-05D8-4F09-BEE9-07921BE9C8E7Q35654205-86A210A1-7DF4-42D0-B10F-97B64522C9AEQ35682682-D6A1C8BC-292D-4BAB-A552-3FF3E08D4167Q35769584-07A2E67D-0FF3-4663-B76E-CD6A9F9A4E33Q35879321-8F4EB453-DA4F-4C26-8888-9AEEA14CBAB4Q35939660-B9AEBEC8-7A4C-4706-90DB-8A0AD1686FA5Q36394674-06B0FC4C-AC9D-4058-AB9F-2AD77CBD7700Q36859559-3A9E1BAC-3F2D-4E24-B600-CC27D908AD70Q37015969-94B7E238-7051-49FA-AFD6-5736519CF75DQ37275418-A9A98776-BA29-4F83-BE1D-2454860A70BDQ37348414-ECFA91A5-AB36-4025-9297-5954AD42A9ECQ37670209-B1F3B112-8226-4589-AD95-11E9FBBB9D78Q38020941-7AF99034-F200-4352-A802-CD950C29A8A2Q38026900-8D745D9D-95EA-463B-9213-903A881B8FB0Q38026956-C3E65F93-CE5C-4C55-AA9F-ACB54541CA90Q38036773-0463F051-A4A5-4D99-BE75-28B3171939BDQ38066566-B69C5E5E-A907-4298-837E-ECE1B19F5F42Q38134109-634C097B-6B1F-4B76-8743-AE1D92ABCDB4Q38175521-17C8E2AC-5252-41A3-AD41-3F46BBF1A28FQ38219482-0A6F5E22-BD10-4202-8440-738F5A96534EQ38266329-4530EB20-79BD-4719-AD5A-C3D82A88C880Q38570757-2BC07084-C214-4441-9AA8-564A4084EDE2Q38580783-8AE88B3F-9D37-465F-8637-4C316439BBCAQ38642435-3254EC7D-4479-40B0-A04C-DD090EA2FD3AQ38806457-440057A8-D1E2-4B18-BE24-D330F16D785CQ38916838-E6B97CDA-107B-40E3-90C4-0A81236C4137Q39140474-38B1D90D-7F6A-42AB-A94D-965126F922FEQ39375164-8E00ABE9-1F6D-46D2-95F7-34A793B7F574Q41465810-83716F48-4F0D-43C4-B771-773C73B420BBQ41504692-DFDC16D4-B310-4178-BD69-C673AF5E8699Q42008289-D00D320F-7021-4C72-B7CC-A2BDBFA77AB2Q48103387-6D037B9A-2036-454A-A368-E6281B9A4775Q48111094-D80F06DE-B619-435E-B164-0EA397D23BC0Q50070044-54907566-EC3A-48D3-A458-E2C4CC481C31
P2860
Liraglutide as additional treatment for type 1 diabetes.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Liraglutide as additional treatment for type 1 diabetes.
@en
Liraglutide as additional treatment for type 1 diabetes.
@nl
type
label
Liraglutide as additional treatment for type 1 diabetes.
@en
Liraglutide as additional treatment for type 1 diabetes.
@nl
prefLabel
Liraglutide as additional treatment for type 1 diabetes.
@en
Liraglutide as additional treatment for type 1 diabetes.
@nl
P2093
P356
P1476
Liraglutide as additional treatment for type 1 diabetes.
@en
P2093
Ajay Chaudhuri
Ajay Varanasi
Antoine Makdissi
Deepti Rawal
Mehul Vora
Natalie Bellini
Paresh Dandona
Sandeep Dhindsa
P356
10.1530/EJE-11-0330
P577
2011-06-06T00:00:00Z